Scarica l'app Stockscreener
0.7115
4.63%
0.0315
Pre-mercato:
.71
-0.0015
-0.21%
Precedente Chiudi:
$0.68
Aprire:
$0.695
Volume 24 ore:
2.97M
Relative Volume:
0.79
Capitalizzazione di mercato:
$154.39M
Reddito:
-
Utile/perdita netta:
$-83.01M
Rapporto P/E:
-1.51
EPS:
-0.4712
Flusso di cassa netto:
$-64.63M
1 W Prestazione:
+1.89%
1M Prestazione:
-17.01%
6M Prestazione:
+6.67%
1 anno Prestazione:
+23.95%
Intervallo 1D:
$0.6888
$0.7395
Intervallo di 1 settimana:
$0.675
$0.74
Portata 52W:
$0.5316
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Nome
Tenaya Therapeutics Inc
Settore
Industria
Telefono
415-865-2066
Indirizzo
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7115 | 155.96M | 0 | -83.01M | -64.63M | -0.4712 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-10 | Iniziato | William Blair | Outperform |
| 2023-11-30 | Iniziato | Leerink Partners | Outperform |
| 2022-06-15 | Iniziato | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics (TNYA) Q1 2026 Earnings: EPS Miss Reflects R&D Investment as Company Advances PipelineNegative Surprise Momentum - newsline.com
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TNYA Q1 2026 Earnings: Slightly Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4 - Moomoo
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCMSlideshow (NASDAQ:TNYA) 2026-06-03 - Seeking Alpha
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in... - markets.businessinsider.com
Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms - TradingView
Tenaya reports interim data from gene therapy trial for rare heart condition - Investing.com
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - The Manila Times
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym - StreetInsider
Gene therapy eases genetic heart condition in small Tenaya trial - Stock Titan
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - The Manila Times
Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - Investing News Network
Tenaya to present gene therapy trial data Wednesday By Investing.com - Investing.com South Africa
Tenaya to present gene therapy trial data Wednesday - Investing.com
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 - Quiver Quantitative
Tenaya Therapeutics to Announce New Interim Data from - GlobeNewswire
Tenaya Therapeutics, Inc. Announces Amended and Restated 2021 Equity Incentive Plan and SEC Filing Details - Minichart
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike - Stock Titan
Tenaya director granted options for 120,000 shares | TNYA Insider Trading - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) awards director 120,000 options at $0.7989 - Stock Titan
Tenaya (TNYA) director receives 120K stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) director June Lee granted 120,000 stock options - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options grant - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) boosts share pool in revised equity plan - Stock Titan
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 - Investing News Network
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference on May 29, 2026 - geneonline.com
Tenaya Therapeutics to present at Jefferies Global Healthcare Conference 2026 in June - Pluang
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference June 2026 - Quiver Quantitative
Tenaya Therapeutics Q1 2026 Earnings: Narrow Miss on Earnings as Biotech Firm Reports No RevenueEPS Miss Report - newsline.com
What do we know so far from TN-201 trial? - Moomoo
TN-201 and TN-401 - Moomoo
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements - MSN
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares - Investing.com UK
Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale - Investing.com UK
Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale By Investing.com - Investing.com India
Tenaya (TNYA) CEO sells 3,390 shares tied to RSU tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) CMO sells 3,121 shares for tax withholding - Stock Titan
Tenaya Therapeutics (TNYA) SVP sells 1,485 shares to cover RSU taxes - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA) - The Globe and Mail
Tenaya Therapeutics, Inc. (TNYA) reports Q1 loss, misses revenue estimates - MSN
Tenaya Therapeutics Inc Azioni (TNYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tenaya Therapeutics Inc Azioni (TNYA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tingley Whittemore | Chief Medical Officer |
May 18 '26 |
Sale |
0.79 |
3,121 |
2,477 |
215,497 |
| Higa Tomohiro | SVP, Finance |
May 18 '26 |
Sale |
0.79 |
1,485 |
1,178 |
118,267 |
| COLUMN GROUP III GP, LP | 10% Owner |
Feb 25 '26 |
Sale |
0.56 |
3,511,826 |
1,975,051 |
0 |
| COLUMN GROUP III GP, LP | 10% Owner |
Feb 24 '26 |
Sale |
0.62 |
658,440 |
405,138 |
1,649,281 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):